| Similar Articles |
|---|
 |
The Motley Fool
October 20, 2006
John Reeves |
7 More Surprising 1-Star Stocks Can these stocks keep up the momentum? Discovery Laboratories... SIRVA... Foxhollow Technologies... Realogy... Cephalon... Oceaneering International... Medis Technologies...   |
The Motley Fool
October 3, 2006
John Reeves |
7 Surprising Stocks Can these stocks keep up the momentum? NutriSystem... Take-Two Interactive... CROCS... Research In Motion... Openwave Systems... Pier 1 Imports... etc. |
The Motley Fool
October 11, 2006
John Reeves |
7 Surprising One-Star Stocks Can these stocks keep up the momentum? Restoration Hardware... Marine Products... AMR Corp... Worldspace Corporation... etc. |
The Motley Fool
October 5, 2006
John Reeves |
7 More Surprising Stocks Are these stocks ripe for the picking? LCA-Vision... Helix Energy Solutions Group... Silver Wheaton... Peru Copper... Pan American Silver... etc. |
The Motley Fool
October 9, 2006
Brian Lawler |
New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up. |
The Motley Fool
September 24, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars. Obagi Medical Products... Red Hat... Zhongpin Inc... etc. |
The Motley Fool
March 13, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: Schering-Plough... AutoZone... |
The Motley Fool
April 7, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: United States Natural Gas Fund... Arena Pharmaceuticals... |
The Motley Fool
May 13, 2009 |
2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Questcor Pharmaceuticals... H&R Block, Inc. ... |
The Motley Fool
July 23, 2011 |
Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
October 30, 2009 |
2 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs: Dr. Reddy's Laboratories... HMS Holdings Corp... |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
The Motley Fool
March 12, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: CV Therapeutics... AutoZone... |
The Motley Fool
July 25, 2011 |
Digital River Earnings Preview Digital River will unveil its latest earnings on Thursday, July 28. |
The Motley Fool
July 1, 2009 |
3 Stocks Hitting High Notes These stocks have hit new highs. Take a look at: Teva Pharmaceutical... Air Transport Services... STEC, Inc. ... |
The Motley Fool
August 24, 2009 |
2 Stocks Hitting High Notes Dr Pepper Snapple Group... Wyeth... etc. |
The Motley Fool
January 23, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Geron... American Science & Engineering... |
The Motley Fool
March 4, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: King Pharmaceuticals... GMX Resources... General Electric... |
The Motley Fool
July 27, 2007 |
Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
April 6, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Baxter International... Abbott Laboratories... |
The Motley Fool
January 29, 2009 |
2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at Novartis... Textron... |
The Motley Fool
July 23, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars. TEPPCO Partners, NVE, and McAfee are advancing. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
July 17, 2008
Dan Dzombak |
3 Stocks Hitting High Notes These three stocks are bucking the trend by hitting new highs. Take a look at: Darling International... Barr Pharmaceuticals... Flower Foods... |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
The Motley Fool
February 9, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Myriad Genetics... Hot Topic... |
The Motley Fool
November 23, 2009 |
Casual Male Retail Group, Inc.: Warming Up or Cooling Off? What we think about the direction of this company's stock. |
BusinessWeek
August 22, 2005
Gene G. Marcial |
New River May Have A "Blockbuster" For ADHD New River Pharmaceuticals has yet to make a dime - but investors love it. |
The Motley Fool
January 12, 2009 |
2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Satyam Computer... Hansen Medical... |
The Motley Fool
January 21, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Capital One Financial Corp. ... Fundtech Ltd. ... Fifth Third Bancorp... |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
September 25, 2007
Brian Lawler |
Acorda at a Glance Acorda Therapeutics has given astute biotech investors quite a ride over the last 12 months following positive results for their lead drug, Fampridine-SR. That drug now takes another step towards FDA approval. Investors, take note. |
The Motley Fool
September 26, 2006
Brian Lawler |
Four-Bagger Biotech in One Day Acorda's shares zoomed up, but potential investors should be cautious. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
October 19, 2007
Tim Beyers |
Hot Stocks You're Buying Now The top three performing industries in the past 30 days have been dry-bulk shipping, Chinese Industries, and Greek companies. Here are some of the hottest stocks in those segment: Omega Navigation Enterprises... China Fire & Security...Navios Maritime... |
The Motley Fool
October 19, 2010
Travis Hoium |
Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
May 18, 2004
Selena Maranjian |
Places for Great Investment Ideas There are some good investment newsletters out there, even from us. |
The Motley Fool
November 2, 2006
Seth Jayson |
Guess? Stumps Us Chumps Here is a simple story of a reformed apparel company that is still making great strides in its operations, with the result that even mediocre sales growth brings impressive benefits to the bottom line. Investors, take note. |
The Motley Fool
October 15, 2009
Robert Steyer |
Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
Real Estate Portfolio
May/Jun 2002
Lauren Raymond |
Nobody's Fool Real estate investors of all levels turn to The Motley Fool's discussion board to ask questions, share information and learn from peers... |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
October 12, 2006
David Meier |
Why I Prefer Main Street Here's why investing from Main Street is better than investing from Wall Street: No short-term performance incentives... Having a life outside of Wall Street... etc. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
May 11, 2011 |
One Stem Cell Stock to Avoid Our investing community's latest short pick -- Pluristem Therapeutics. |
The Motley Fool
July 2, 2009
Brian Orelli |
Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday. |
The Motley Fool
October 7, 2009
Robert Steyer |
Acorda's Upcoming Excitement Acorda is seeking FDA approval for a pill to improve the walking ability of multiple sclerosis patients. |
